Repeat-unit representation; n varies across the polymer distribution. No single-chain SMILES or exact molecular weight is assigned.
OL-56 (HO-PEG-Ste)
OL-56 (HO-PEG-Ste) is a hydroxyl-terminated PEG stearate for research on PEG-lipid components of lipid nanoparticles. It combines a PEG chain with a single C18 fatty-acid anchor through an ester linkage.
Contact us for available pack sizes, price, COA and SDS. For laboratory research use only.
We match the best price and quality on market.
Specifications
| Catalog number | DCL0026 |
|---|---|
| Synonyms | OL56; HO-PEG-Ste; HO-PEG-stearate; hydroxyl-terminated PEG stearate |
| Lipid anchor | Stearate (C18) |
| PEG terminus | Hydroxyl (–OH) |
| Linkage | Ester |
| Reference grade | 2,000 (reference catalog designation; PEG-chain versus full-conjugate basis remains unconfirmed) |
| Molecular weight | Polymer distribution; request the batch-specific specification |
| CAS number | Not assigned to this exact grade |
| Purity / storage | Request the batch-specific COA and handling instructions |
The reference catalog lists “2,000”; its molecular-weight basis has not been verified. Do not use this number as an exact full-conjugate molecular weight.
Formulation & Performance
Published results below describe complete mRNA–LNP formulations containing OL-56. They do not establish the efficacy of OL-56 alone or the performance of a supplied batch.
Reported lipid components: SM-86, OL-56, DSPC and cholesterol. The cited methods do not provide a verified four-lipid molar ratio; no ratio is assigned here.
| Study / formulation | Diameter | PDI | Encapsulation |
|---|---|---|---|
| Preclinical · mRNA-3927 [1] | 70 nm | 0.14 | >96% |
| Preclinical · mRNA-3705 [1] | 71 nm | 0.07 | 97% |
| Preclinical · mRNA-3210 [1] | 77 nm | 0.13 | 95% |
| Phase 1/2 study · mRNA-3927 [2] | 87 nm | 0.20 | >96% |
Study [1] reports microfluidic mixing at an aqueous:ethanol volume ratio of 3:1. This is not a lipid molar ratio or an N/P ratio.
References
- Baek R, et al. Characterizing the mechanism of action for mRNA therapeutics for the treatment of propionic acidemia, methylmalonic acidemia, and phenylketonuria. Nature Communications (2024). Full text.
- Koeberl D, et al. Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia. Nature 628, 872–877 (2024).
Related formulation components
DSPC · DC57005 · Cholesterol · DCD-041
SM-86 is a reported formulation component. A substitute lipid is not assigned.
Documents & quotation
Contact us for available pack sizes, price, COA and SDS. For laboratory research use only.
Request COA / SDS / quotation Online datasheet